secwatch.observer — SEC 8-K summary
======================================

Issuer:     SpringWorks Therapeutics, Inc. (—)
CIK:        0001773427
Form:       8-K
Filed at:   2024-07-30T23:59:59+00:00
Accession:  0001104659-24-083955
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SpringWorks appoints Martin Mackay to Board of Directors effective July 29, 2024
--------------------------------------------------------------------------------

- Mr. Mackay is independent under Nasdaq standards and serves as a Class II director until 2027 annual meeting.
- Initial grants: options for 29,445 shares at $36.80 exercise price; RSUs for 9,963 shares.
- Mackay brings 30+ years pharma/biotech R&D experience from Pfizer, AstraZeneca, and Alexion.
- Compensation follows company's non-employee director policy; standard indemnification agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1773427/000110465924083955/0001104659-24-083955-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1773427/000110465924083955/tm2420401d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-083955

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer